Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Trial Profile

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2018

At a glance

  • Drugs AKB 9778 (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms TIME-2b
  • Sponsors Aerpio Pharmaceuticals
  • Most Recent Events

    • 15 May 2018 According to an Aerpio Pharmaceuticals media release, top-line data from this study is expected in in the second quarter of 2019.
    • 08 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 29 Jun 2017 According to an Aerpio Pharmaceuticals media release, the company has initiated patient dosing in this trial. Victor H. Gonzalez has enrolled the first patient in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top